{"id":27636,"date":"2015-08-26T16:22:24","date_gmt":"2015-08-26T20:22:24","guid":{"rendered":"http:\/\/sciencebusiness.technewslit.com\/?p=27636"},"modified":"2016-06-11T12:26:03","modified_gmt":"2016-06-11T16:26:03","slug":"pharma-research-group-partner-on-meningitis-therapy","status":"publish","type":"post","link":"https:\/\/technewslit.com\/sciencebusiness\/?p=27636","title":{"rendered":"Pharma, Research Group Partner on Meningitis Therapy"},"content":{"rendered":"
\"Cryptococcus<\/a>
Cryptococcus neoformans fungus (Centers for Disease Control and Prevention)<\/figcaption><\/figure>\n

26 August 2016. A collaboration between a company developing anti-fungal drugs and research group specializing in fungal infections aims to advance\u00a0a new type of therapy for\u00a0cryptococcal meningitis, a life-threatening\u00a0infection affecting the brain and\u00a0spinal cord. Financial details of the partnership between\u00a0Viamet Pharmaceuticals<\/a> in Research Triangle Park, North Carolina\u00a0and\u00a0Mycoses Study Group Education and Research Consortium in Birmingham, Alabama were not disclosed.<\/p>\n

Cryptococcal meningitis<\/a> is\u00a0a fungal infection of the tissues covering the brain and spinal cord, caused by\u00a0the fungus Cryptococcus neoformans<\/a> <\/em>found in soil worldwide. The disease usually affects people with weakened immune systems, such as those with AIDS,\u00a0cirrhosis, diabetes, and leukemia. People who become infected normally breathe in the microscopic fungus. Symptoms include headache, fever, hallucinations, nausea, vomiting, sensitivity to light, and confusion or disorientation.<\/p>\n

Viamet Pharmaceuticals discovers and develops therapies for fungal infections. The company says its technology<\/a> combines computational techniques with chemical and biological processes to discovery therapy candidates that block the actions of metalloenzymes<\/a>, proteins that function as enzymes but have metal ions in their chemistry. Viamet\u00a0built a library of 200\u00a0metalloenzymes and inhibitors, including those with anti-fungal properties, from which it develops therapeutics.<\/p>\n

The company’s lead product<\/a> is an\u00a0anti-fungal candidate code-named VT-1161 now being tested in clinical trials to treat vaginal yeast infections and onychomycosis, a type of toenail fungus. Viamet also has a candidate VT-1129 designed to treat cryptococcal meningitis. All three therapies target the metalloenzyme CYP51<\/a> for controlling fungus infections. The company says VT-1129 in preclinical tests shows it can eradicate the fungus causing\u00a0cryptococcal meningitis from the central nervous system.<\/p>\n

The\u00a0Mycoses Study Group Education & Research Consortium, that started about a year ago<\/a>, supports research and continuing education on invasive fungal infections. The consortium is an offshoot and successor\u00a0to\u00a0a previous organization,\u00a0Mycoses Study Group, that investigated rare fungal infections. The\u00a0new consortium<\/a> is made up of research labs that generate an annual scientific\u00a0agenda and\u00a0conference.<\/p>\n

The collaboration is expected to combine\u00a0the clinical experience of the\u00a0Mycoses Study Group Education & Research Consortium with the drug discovery and\u00a0development work of Viamet. The initial focus of the partnership will be Viamet’s VT-1129 candidate, for which clinical tests are planned later this year.<\/p>\n

Read more:<\/p>\n